Main navigation
Reviewed by Dr. Sneha Lata
Gynaecologist & IVF Specialist
10+ years of experience
Expert Verified
How is this page expert verified?
This information has been reviewed and approved by an experienced fertility specialist at Indira IVF to provide accurate and up-to-date guidance for our readers.
Overview
If your doctor has mentioned OHSS during your IVF treatment, or you have started feeling bloated and uncomfortable after your stimulation injections, it is completely understandable to feel worried. Ovarian hyperstimulation syndrome (OHSS) can happen when the ovaries respond more strongly than expected to the hormone medicines used during IVF to help develop several eggs.
For most women, OHSS is mild, and the symptoms improve on their own within a week or two. In some cases, however, the symptoms can be more noticeable and may need medical care. Knowing what to look out for can make the experience feel a little less overwhelming.
Ovarian hyperstimulation syndrome (OHSS) refers to a condition where the ovaries become swollen and tender due to an increased reaction to fertility medicines. In a regular menstrual cycle, one ovary releases a single egg. The process of stimulation for IVF involves the injection of hormones to cause multiple eggs to be produced by the ovaries. This may also lead to the ovaries producing certain chemicals that cause fluid to leak into the abdominal area, and may result in bloating and discomfort. According to a 2024 study published in the Journal of Personalized Medicine, OHSS is one of the most frequent complications, accounting for 30% of IVF cycles.
OHSS is caused by the same fertility medicines that help your ovaries produce multiple eggs, particularly the injection used to trigger final egg maturation. Two parts of the process matter most:
Gonadotrophins, injectable hormones such as FSH (a hormone that stimulates egg growth), help many eggs develop at once during stimulation instead of just one. When the ovaries overrespond, they produce many follicles (fluid-filled sacs, each holding a developing egg) and raise blood oestrogen, making them more likely to release the chemicals behind OHSS.
Human chorionic gonadotropin (hCG) is the 'trigger injection' that helps eggs finish maturing roughly 36 hours before retrieval. Since it resembles a pregnancy hormone, hCG prolongs and intensifies the ovaries' response, which is why it is closely linked to OHSS. Doctors sometimes use an alternative trigger in higher-risk women.
Signs and symptoms of ovarian hyperstimulation syndrome usually appear within a week or two of the trigger injection and range from mild to severe.
Mild OHSS is the most common form. You may notice abdominal bloating, mild pelvic discomfort, nausea, and fullness in the lower abdomen. These symptoms usually settle on their own within a week.
Moderate OHSS adds vomiting, diarrhoea and rapid weight gain from fluid retention. Severe OHSS includes gaining more than a kilogram in a single day, severe abdominal pain, persistent vomiting, breathlessness, a tight, swollen abdomen and passing very little urine. These are signs that the fluid shift needs medical review.

Call your clinic for rapid weight gain, severe abdominal pain, breathlessness, or noticeably less urine, so your doctor can check your hydration and kidneys before symptoms progress.
Certain factors make some women more likely to develop OHSS, which is why your fertility team assesses your risk before stimulation begins.
Having had OHSS in an earlier IVF cycle makes it more likely to happen again, so your doctor may adjust your protocol.
Polycystic ovary syndrome (PCOS) is a hormonal condition in which the ovaries contain many small, immature follicles. These ovaries tend to respond more strongly to stimulation medicines, which raises OHSS risk.
Women with high anti-Müllerian hormone (AMH, a blood marker of egg supply) who produce many follicles during stimulation are called high responders. This is one of the strongest predictors of who is at risk of OHSS during IVF.
A few other factors can also raise OHSS risk:
OHSS is diagnosed through your symptoms, a physical exam, and tests checking how much fluid has shifted into your abdomen.
Your doctor will ask about your symptoms and how many days have passed since your trigger injection, then examine your abdomen for tenderness and swelling.
An ultrasound shows the size of your ovaries and any fluid collecting in your abdomen. Blood tests check your haematocrit (the concentration of red blood cells, which rises when fluid leaks from blood vessels), kidney function and electrolytes, helping your doctor grade OHSS severity.
Doctors classify OHSS into four severity levels:
Mild OHSS brings abdominal bloating, mild discomfort, and slightly enlarged ovaries, with no significant change on blood tests.
Moderate OHSS adds nausea, vomiting and visible abdominal fluid on ultrasound, with more enlarged ovaries.
Severe OHSS brings a tense, fluid-filled abdomen, breathlessness, a marked rise in haematocrit, and reduced urine output, usually needing hospital monitoring.
Critical OHSS is rare, involving blood clots, significant kidney impairment or fluid around the lungs, and needs intensive hospital care.
OHSS itself does not damage your ovaries or reduce your long-term fertility. If you develop moderate or severe OHSS, your fertility team may freeze your embryos and postpone the transfer to a later cycle, once your body has recovered.
A common concern is whether OHSS can affect pregnancy after IVF once a cycle has triggered symptoms. As per the American Society for Reproductive Medicine, OHSS does not harm a developing pregnancy, though symptoms can last two to three weeks longer, since pregnancy produces more hCG.
Knowing how to prevent OHSS during IVF starts with adjusting your protocol to your risk. Your fertility specialist has several tools:
If you are a high responder, your doctor may prescribe a lower stimulation dose from the start, reducing the follicles that develop and lowering OHSS risk.
Regular ultrasound scans and blood tests during stimulation let your doctor track your follicles and adjust medication if your ovaries respond faster than expected.
In high-risk women, doctors often use a GnRH agonist (a medicine based on gonadotrophin-releasing hormone, which controls egg release) as the trigger instead of hCG, since it lowers OHSS risk considerably. A GnRH antagonist stimulation protocol, rather than a longer agonist one, also helps.
If OHSS risk is high after retrieval, your clinic may freeze all suitable embryos and delay transfer to a later cycle. This 'freeze-all' approach avoids the extra hCG an early pregnancy would add to an already overstimulated system.
OHSS can be a risk factor in fertility treatment but with right treatment it can be avoided.
— Dr. Kumari Namrata
OHSS treatment and recovery time depend on how severe your symptoms are and whether pregnancy occurs in the same cycle. According to a 2018 study published in Journal of Ovarian Research, mild to moderate OHSS usually resolves within one to two weeks without pregnancy. Pregnancy in the same cycle can extend symptoms by several weeks, since it keeps producing hCG. Severe OHSS takes longer still, and your doctor will monitor you with blood tests until fluid balance and kidney function return to normal.
OHSS is an emergency situation when it impacts the ability to breathe, circulation, or even the functioning of the kidneys. Seek medical attention immediately in case of severe breathlessness, chest pain, calf pain and swelling (possibly due to a blood clot), lack of urine, or abdominal pain despite painkillers.
For most women who get OHSS during the IVF process, it is a mild and transient experience that resolves itself before their pregnancy test is expected. There are many techniques to reduce the risk of this happening; the fertility specialists can either use less intense ovulation stimulation drugs, another trigger shot, or delay the embryo transfer process.
Understanding the symptoms and warning signs of OHSS and the associated risk factors gives both you and your physician the means of recognising early changes. It will not help with all of the uncertainties the IVF procedure holds, but at least it will give you an understanding of what your body is telling you.
OHSS happens when the ovaries react more strongly than expected to the hormone injections used during IVF stimulation, causing them to swell and leak fluid into the abdomen. It is a known, monitored risk, not a sign your treatment has gone wrong.
The earliest signs are usually abdominal bloating, mild pelvic discomfort and a feeling of fullness within a few days of the trigger injection. Mild nausea is also common, and these early signs do not necessarily mean it will become severe.
Women with PCOS, those who have had OHSS before, and women who produce a high number of follicles during stimulation face a higher chance of developing it. Younger women and those with a lower body weight are also somewhat more at risk.
Prevention usually means tailoring your medication dose to your ovarian response, monitoring you closely and choosing a lower-risk trigger injection for high responders. Freezing embryos and delaying transfer can also help.
Mild OHSS is usually managed at home with rest, fluids and simple pain relief, with regular check-ins with your clinic. Severe OHSS is treated in a hospital with intravenous fluids, blood-thinning medicine and, if needed, fluid drainage.
Most mild and moderate cases resolve within one to two weeks without pregnancy. If pregnancy occurs, symptoms can continue for a few additional weeks, since pregnancy hormones keep the ovaries active longer.
OHSS does not harm the pregnancy itself or how it develops. Symptoms may last longer if you are pregnant, since hCG keeps the ovaries stimulated, but this is a matter of duration, not risk to the baby.
Contact your clinic promptly for rapid weight gain, severe or worsening abdominal pain, breathlessness or a significant drop in urine output. It is also worth calling if you are simply unsure whether what you feel is normal.
For patients concerned about ovarian hyperstimulation syndrome (OHSS), choosing an IVF centre with experience in risk assessment and prevention is important. Indira IVF is one option to consider for fertility evaluation and personalised treatment planning. Ask the fertility specialist how the clinic assesses OHSS risk, individualises ovarian stimulation protocols, monitors the response to fertility medications, and uses preventive measures when needed. The risk of OHSS can often be reduced through appropriate clinical strategies, although it cannot always be eliminated. The most suitable approach depends on individual risk factors and medical history.
Take the Next Step in Your Fertility Journey
Schedule your visit today!
Disclaimer
*Zero Interest EMI Plans: Provided by third party financial institution, subject to conditions.
*72%+ Success Rate: Overall IVF success rate is calculated as the total number of positive pregnancy blood tests resulting from IVF procedures at our own and operated clinics in India divided by the total number of pregnancy blood tests reported from IVF procedures at our own and operated clinics in India during financial year ending 31st March 2025.
*Best IVF/Fertility Chain of the Year: Received the “Best IVF/Fertility Chain of the Year – National” award at the IVF Excellence Awards by Voice of Healthcare, 2024.
*Most Trusted IVF Chain: Received the “Most Trusted IVF Chain” award by The Knights – MY FM Group, 2019.
* Please note: The information provided on website serves as a general guide and does not constitute medical advice. We strongly advise consulting a certified fertility expert for professional assessment and personalized treatment recommendations.
*Indira IVF is the Largest IVF Chain of Hospitals: India’s largest IVF service provider by the number of clinics and in terms of revenue and EBITDA among the peers in the consideration set comprising single specialty IVF players in Financial Year 2024, according to the report titled ‘Assessment of the healthcare delivery sector in India with focus on ART healthcare market’ issued by CRISIL Market Intelligence & Analytics in January 2025.